Professor Shampa Das BSc, PhD
Head of the Department / Professor of Antimicrobial Therapeutics Pharmacology & Therapeutics
- +44 (0)151 795 5480
- Work email Shampa.Das@liverpool.ac.uk
- Personal Websitehttps://www.liverpool.ac.uk/apt
Research
Research Grants
Expansion of assessment pharmacodynamics of flomoxef-fosfomycin and fosfomycin/amikacin combinations for neonatal sepsis using the HFIM
GARDP FOUNDATION (SWITZERLAND)
August 2022 - March 2024
Development of a new rabbit model to characterise antifungal drug resistance
FOOD AND DRUG ADMINISTATION (USA)
September 2023 - September 2025
Hit Compound to Potentiate the Activity of Amikacin for Acinetobacter baumannii (Chequerboard)
GARDP FOUNDATION (SWITZERLAND)
October 2023 - January 2024
Novel Gram-Negative Antibiotic Now (T7.2 & T7.4) (GNA NOW)
EUROPEAN COMMISSION
July 2019 - June 2025
Pharmacodynamics of Antimicrobial Combinations for Neonatal Sepsis in Low-To-Middle Income Countries
GARDP FOUNDATION (SWITZERLAND)
November 2018 - July 2021
NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (HPRU EZI)
DEPARTMENT OF HEALTH & SOCIAL CARE (UK)
April 2020 - March 2025
Assessment of the PKPD of BWC0977
BUGWORKS RESEARCH INDIA PVT. LTD. (INDIA)
September 2019 - July 2024
An evidence-based preclinical framework development antimicrobial therapeutics cystic fibrosis
CYSTIC FIBROSIS TRUST (UK)
October 2021 - September 2025
Pharmacokinetic-Pharmacodynamic assessment of BV100 in the hollow fibre infection model WP1
BIOVERSYS (SWITZERLAND)
April 2021 - August 2024
ANT3310 - Assessment of the pharmacodynamics of ANT3310 a serine beta-lactamase inhibitor
ANTABIO (FRANCE)
January 2020 - December 2020
AAI101 and Cefepime in Epithelial Lining Fluid and Plasma in Healthy Volunteers REC
ALLECRA THERAPEUTICS GMBH (GERMANY)
January 2018 - September 2022
Pharmacokinetic-Pharmacodynamic analyses of novel metallo-betalactmase inhibitors in multidrug resistant Gram negative infections
ANTABIO (FRANCE)
May 2018 - October 2019
Assessment of tebipenem in the hollow fibre
SPERO OPCO INC (USA)
August 2016 - July 2018
PK-PD analyses of cefepime and AAI101 against MDR enterobacteriaceae
ALLECRA THERAPEUTICS GMBH (GERMANY)
October 2017 - October 2018